Hypermagnesemia in critically ill patients with cancer: A case report
- Authors:
- Vijay Raju Krupesh
- Hrishi Varayathu
- Vinu Sarathy
- Gogana Prabhakar Rao
- Yogendra Shrestha
- Radheshyam Naik
View Affiliations
Affiliations: Healthcare Global Enterprises Limited, Sampangi Ram Nagar, Bangalore 560027, India
- Published online on: April 21, 2021 https://doi.org/10.3892/mco.2021.2285
-
Article Number:
123
-
Copyright: © Krupesh
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Hypermagnesemia is often an under reported finding in critically ill patients with cancer. Hypomagnesemia is a commonly encountered electrolyte abnormality in patients with cancer that is primarily caused by a reduced intake, secondary to chemotherapeutic drugs and malnutrition. Hypermagnesemia is rarely observed in patients with normal renal function, as excess intake can be compensated by renal excretion. However, in critically ill patients with reduced renal function, hypermagnesemia can add further to complications and increase mortality. Drugs such as lactulose, antacids, fentanyl and peptide hormones, including vasopressin, can further increase chances of hypermagnesemia, particularly when patients demonstrate decreased renal function and multiple organ failure. Prudence and caution must therefore be exercised while using these agents in critically ill patients with cancer to avoid increased complications and mortality. Herein, the current study reports three cases of critically ill patients with cancer admitted into intensive care who had refractory hypermagnesemia.
View References
|
1
|
Berardi R, Torniai M, Lenci E, Pecci F,
Morgese F and Rinaldi S: Electrolyte disorders in cancer patients:
A systematic review. J Cancer Metastasis Treat. 5(79)2019.
|
|
2
|
Deheinzelin D, Negri EM, Tucci MR, Salem
MZ, Da Cruz VM, Oliveira RM, Nishimoto IN and Hoelz C:
Hypomagnesemia in critically ill cancer patients: A prospective
study of predictive factors. Braz J Med Biol Res. 33:1443–1448.
2000.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Felsenfeld AJ, Levine BS and Rodriguez M:
Pathophysiology of calcium, phosphorus, and magnesium dysregulation
in chronic kidney disease. Semin Dial. 28:564–577. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Swaminathan R: Magnesium metabolism and
its disorders. Clin Biochem Rev. 24:47–66. 2003.PubMed/NCBI
|
|
5
|
Cascella M and Vaqar S: Hypermagnesemia.
In: StatPearls [Internet]. StatPearls Publishing, Treasure Island,
FL, 2021.
|
|
6
|
Cheungpasitporn W, Thongprayoon C and Qian
Q: Dysmagnesemia in hospitalized patients: Prevalence and
prognostic importance. Mayo Clin Proc. 90:1001–1010.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Seki N, Hamano H, Iiyama Y, Asano Y,
Kokubo S, Yamauchi K, Tamura Y, Uenishi K and Kudou H: Effect of
lactulose on calcium and magnesium absorption: A study using stable
isotopes in adult men. J Nutr Sci Vitaminol (Tokyo). 53:5–12.
2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dai LJ, Bapty B, Ritchie G and Quamme GA:
Glucagon and arginine vasopressin stimulate Mg2+ uptake in mouse
distal convoluted tubule cells. Am J Physiol. 274:F328–F335.
1998.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Quamme GA, Schlingmann KP and Konra M S:
Mechanisms and disorders of magnesium metabolism. In: Seldin and
Giebisch's The Kidney. Alpern RJ, Herbert SC (eds). Volume 2. 4th
edition. Academic Press. pp 1747-1767, 2008.
|
